Earnings Outlook For Genmab
Portfolio Pulse from Benzinga Insights
Genmab (NASDAQ:GMAB) is scheduled to release its quarterly earnings report on February 14, 2024, with analysts estimating an EPS of $4.02. Investors are hopeful for a beat on this estimate and positive guidance for future growth. Genmab's stock performance has been negative over the last year, with a 31.7% decline, and shares were trading at $27.49 as of February 12. The company's past earnings performance shows a mix of beats and misses, with the stock price reacting accordingly.
February 13, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab is expected to report an EPS of $4.02 for the upcoming quarter. The stock has seen a 31.7% decline over the past year, with current trading at $27.49. Past earnings have shown mixed results, affecting stock price movements.
Given the anticipation of a positive earnings report and potential guidance for future growth, there's a short-term bullish sentiment. However, the stock's past year performance and the mixed results in previous quarters introduce caution. The expectation of a beat on the EPS estimate and positive future guidance could lead to a short-term positive impact on GMAB's stock price, but investor sentiment will be crucial.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100